How it works
Schedule a Meeting
Connect with our business and scientific teams to explore strategic access and discuss how to drive your oncology innovation forward.
Which tumor models are you interested in testing?
What defines the Ideal Tumor Model?
Biological Complexity That Mirrors Human Tumors
Cypre’s models go beyond spheroids and basic organoids—incorporating stromal fibroblasts, ECM tuning, and immune cells to recreate the tumor microenvironment (TME) in vitro. This layered architecture captures the real barriers to therapeutic efficacy, from immune suppression to delivery resistance.
Predictive Across Modalities and Mechanisms
Built for versatility, our models support the screening of small molecules, ADCs, bispecifics, checkpoint inhibitors, and novel combinations. Whether you're optimizing leads or exploring new indications, Cypre enables data-driven decisions across therapeutic classes.
High-Throughput Analytics. IND-Caliber Output.
From standardized cytokine profiling to high-content imaging and immune phenotyping, our platform delivers consistent, mechanistic readouts at scale—ready to support go/no-go decisions, regulatory filings, and partnership traction.
What Makes a Smart Drug Panel?
Diverse Cell Line Selection for Translational Relevance
Our panels feature a curated set of tumor models spanning multiple indications, genetic backgrounds, and biomarker profiles—helping you assess drug performance across clinically relevant scenarios.
Consistent, Reproducible Assays Across Conditions
Each panel is built with quality-controlled processes to ensure uniform TME conditions, allowing for apples-to-apples comparisons across indications, targets, and drug classes.
Actionable Data to Guide Portfolio Strategy
Get clear insights into efficacy trends, resistance patterns, and predictive biomarkers that inform your next steps—whether it’s refining candidate selection, validating hypotheses, or identifying ideal responder populations.
How We Help Target Audience Achieve Result
Validated Preclinical Efficacy for a Top-10 Pharma
Antibody-drug conjugates (ADCs) demand physiologically relevant models to test payload delivery, tumor penetration, and cytotoxic impact. Cypre’s 3D tumor organoids incorporate stromal density and immune suppression to replicate the barriers ADCs must overcome—delivering robust efficacy and MOA insights.
Here’s what we accomplished for Boehringer Ingelheim:
Mapping Immune Activation with Predictive Analytics
T cell engagers require immune-competent models to accurately capture activation, infiltration, and tumor cell killing. Cypre’s tri-culture platform—featuring tumor cells, fibroblasts, and PBMCs—enables detailed immunological profiling across a range of tumor indications.
Here’s what we accomplished for Takeda:
De-Risking Development with Immune-Competent 3D Models
Many immunotherapies underperform in clinical trials due to inadequate preclinical modeling. Cypre’s 3D tumor microenvironment assays recreate immunosuppressive dynamics—providing early, predictive insights into responder identification and resistance mechanisms.
Here’s what we accomplished for Genentech:
Precision Oncology Starts with the Right Models
Targeted therapies demand models that reflect real-world genetic complexity. Cypre’s 30- and 42-model PDX panels are genomically annotated to capture critical mutations—empowering sponsors to validate mechanism of action and therapeutic response with precision.
Here’s what we accomplished for Charles River Partners:
Synergy You Can See, Data You Can Trust
Combination regimens require clarity across complex interactions. Cypre’s platform integrates tumor, stromal, and immune compartments—capturing both direct cytotoxicity and immune-mediated responses to dual-modality therapies.
Here’s what we accomplished for an Emerging Biotech:
High-Fidelity Tumor Models for Translational Precision
Cypre’s platform starts with patient-derived xenograft (PDX) cells and builds outward—layering in human fibroblasts, immune cells, and our proprietary VersaGel® hydrogel to recreate the tumor microenvironment with unprecedented realism. This tri-culture system mirrors the architecture, stiffness, and immune dynamics of human tumors, enabling predictive, reproducible insights into efficacy and mechanism of action—all without the need for animal models.
Schedule a ConsultationStandardized Analytics That Drive Confident Decisions
Each study follows a six-point serial dilution format across 96-well plates, delivering high-resolution, mechanistic insights at scale. From tumor killing and growth delay to cytokine profiling, immune infiltration, and flow-based phenotyping, our analytics package generates consistent, publication-ready data. Whether you're advancing ADCs, bispecifics, or novel immunotherapies, Cypre’s standardized readouts help you validate efficacy, uncover MOA, and move faster toward IND milestones.
Schedule a ConsultationA Scalable, Panel-Based Process Built for Drug Development
Cypre’s tumor panels—available in 5-, 30-, and 42-model formats—are genomically annotated and optimized for high-throughput pharmacology screening. Whether you’re prioritizing leads or generating MOA data for regulatory submission, our plug-and-play formats support rapid, reproducible insights. Flexible timelines, consistent outputs, and comprehensive analytics help you move from study initiation to strategic decision-making in as little as 30–45 days.
Schedule a ConsultationAccelerating Immunotherapy Insights with Complex 3D Tumor Models
Boehringer Ingelheim partnered with Cypre to evaluate a panel of T cell engagers across diverse PDX-derived tumor models—each designed to simulate an immune-excluded tumor microenvironment. The objective: assess tumor killing, T cell infiltration, and immune activation markers with greater physiological relevance than standard in vitro systems.
Using our proprietary VersaGel® hydrogel and standardized analytics, Cypre delivered detailed efficacy and MOA insights—including CD3⁺/CD8⁺ infiltration and cytokine profiles—in under 45 days. These results helped refine Boehringer’s lead optimization strategy and supported critical go/no-go decisions.
+
Models Screened across multiple tumor types using the Cypre 3D PDX platform
Multi-modal Analytics
High-content imaging, cytokines, and flow cytometry readouts delivered
Rapid Turnaround
Full reports returned within 6–9 weeks, supporting timely go/no-go decisions
Validated Insights
Data used in ongoing preclinical planning and pipeline strategy
FAQs
How long does it take to get results from a Cypre study?
What data is included in the final deliverable?
How are tumor models selected for a project?
Can these models be used to screen combination therapies?
What’s the process for getting started with a study?What’s the process for getting started with a study?
Let’s Build the Future of Oncology, Together
Partner with Cypre to co-develop translationally validated, IND-ready insights using our complete 3D tumor organoid platform. From immune profiling to custom panels, we’re built for collaboration.
